Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator
January 16, 2024 07:30 ET
|
Emergex Vaccines Holding Ltd
Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point immunotherapeutic candidates with DEKA’s...
Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™
January 03, 2024 11:16 ET
|
Emergex Vaccines Holding Ltd
Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses. Emergex is...
Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch
December 18, 2023 07:00 ET
|
Emergex Vaccines Holding Ltd
Earlier this year, Emergex submitted a notification to the FDA regarding the transfer of ownership of Zosano Pharma’s Microneedle Array Patch (MAP) epidermal drug delivery system to Emergex itself...
Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
November 17, 2023 07:00 ET
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through...
Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
October 05, 2023 07:00 ET
|
Emergex Vaccines Holding Ltd
Emergex and VIC plan to collaborate to further develop and commercialise Emergex’s proprietary T cell-based vaccine candidates as designated in Saudi Arabia and the agreed Territory (including GCC...
Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
July 19, 2023 08:00 ET
|
Emergex Vaccines Holding Ltd
First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated Evidence for generation of virus-specific effector and memory CD8+ T cells Data reinforce findings from trial of...
Emergex Appoints Sir Michael Rake as Board Chairman
June 29, 2023 08:00 ET
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through...
Emergex e IBMP do Brasil Anunciam Colaboração no Desenvolvimento Clínico para Medicamentos Experimentais Relacionados ao Ponto de Regulação Imunológica do Priming de Células T
June 20, 2023 08:00 ET
|
Emergex Vaccines Holding Ltd
A Emergex e o IBMP do Brasil irão cofinanciar estudos de Fase II e Fase III da Emergex no Brasil, para medicamentos experimentais para o tratamento da Febre da Dengue e do Betacoronavírus relacionados...
Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
June 20, 2023 08:00 ET
|
Emergex Vaccines Holding Ltd
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic candidates in Brazil, with potential to...
Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
June 06, 2023 11:45 ET
|
Emergex Vaccines Holding Ltd
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+...